AGXT and primary hyperoxaluria type 1: Current guidelines recommend testing pyridoxine (VB6) responsiveness in all genetically confirmed PH1 [111], although it is expected that full response will mainly occur with the AGXT MiR variants, in particular the p.G170R and p.F152I mutations.